Cyclic guanosine monophosphate and 10-year change in left ventricular mass: the Multi-Ethnic Study of Atherosclerosis (MESA)

References

• Armstrong, P.W., et al., VITALITY-HFpEF Study Group, 2020. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF Randomized Clinical Trial. JAMA, 324 (15), 1512–1521.
   PubMed Web of Science ®Google Scholar
• Bild, D.E., et al., 2002. Multi-Ethnic Study of Atherosclerosis: objectives and design. American journal of epidemiology, 156 (9), 871–881.
   PubMed Web of Science ®Google Scholar
• Borlaug, B.A. and Redfield, M.M., 2011. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation, 123 (18), 2006–2013. discussion 2014.
   PubMed Web of Science ®Google Scholar
• Castro, L.R., et al., 2006. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation, 113 (18), 2221–2228.
   PubMed Web of Science ®Google Scholar
• Choi, E.Y., et al., 2012. N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis. Circulation: heart failure, 5 (6), 727–734.
   PubMed Web of Science ®Google Scholar
• Do Nascimento, G.R., et al., 2009. Research into specific modulators of vascular sex hormone receptors in the management of postmenopausal cardiovascular disease. Current hypertension reviews, 5 (4), 283–306.
   PubMedGoogle Scholar
• Domek-Łopacińska, K.U. and Strosznajder, J.B., 2010. Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Molecular neurobiology, 41 (2-3), 129–137.
   PubMed Web of Science ®Google Scholar
• Eng, J., et al., 2016. Adverse left ventricular remodeling and age assessed with cardiac MR imaging: the Multi-Ethnic Study of Atherosclerosis. Radiology, 278 (3), 714–722.
   PubMed Web of Science ®Google Scholar
• Ghofrani, H.-A., et al., 2013. Riociguat for the treatment of pulmonary arterial hypertension. New England journal of medicine, 369 (4), 330–340.
   PubMed Web of Science ®Google Scholar
• Golshiri, K., et al., 2020. The importance of the nitric oxide‐cGMP pathway in age‐related cardiovascular disease: focus on phosphodiesterase‐1 and soluble guanylate cyclase. Basic & clinical pharmacology & toxicology, 127 (2), 67–80.
   PubMed Web of Science ®Google Scholar
• Greene, S.J., et al., 2013. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. Journal of the American Heart Association, 2 (6), e000536.
   PubMed Web of Science ®Google Scholar
• Guazzi, M., Vicenzi, M., and Arena, R., 2012. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long‐term cardiopulmonary exercise testing placebo‐controlled study. European journal of heart failure, 14 (1), 82–90.
   PubMed Web of Science ®Google Scholar
• Jafari, B. and Mohsenin, V., 2012. Activation of heme oxygenase and suppression of cGMP are associated with impaired endothelial function in obstructive sleep apnea with hypertension. American journal of hypertension, 25 (8), 854–861.
   PubMed Web of Science ®Google Scholar
• Kelly, M.P., 2018. Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. Cellular signalling, 42, 281–291.
   PubMed Web of Science ®Google Scholar
• Lapp, H., et al., 2009. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation, 119 (21), 2781–2788.
   PubMed Web of Science ®Google Scholar
• Lee, D.S., et al., 2009. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction. Circulation, 119 (24), 3070–3077.
   PubMed Web of Science ®Google Scholar
• Macheret, F., et al., 2012. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. Journal of the American College of Cardiology, 60 (16), 1558–1565.
   PubMed Web of Science ®Google Scholar
• Mair, J. and Puschendorf, B., 1998. Is measurement of cyclic guanosine monophosphate in plasma or urine suitable for assessing in vivo nitric oxide production? Circulation, 97 (12), 1209–1210.
   PubMed Web of Science ®Google Scholar
• Mcmurray, J.J., et al., PARADIGM-HF Investigators and Committees, 2014. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England journal of medicine, 371 (11), 993–1004.
   PubMed Web of Science ®Google Scholar
• Natori, S., et al., 2006. Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity. American journal of roentgenology, 186 (6_supplement_2), S357–S65.
   PubMed Web of Science ®Google Scholar
• Redfield, M.M., et al., RELAX Trial, 2013. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA, 309 (12), 1268–1277.
   PubMed Web of Science ®Google Scholar
• Sanchez, O.A., et al., 2015. Increasing NT-proBNP precedes the development of arterial hypertension: the multi-ethnic study of atherosclerosis. Journal of hypertension, 33 (5), 966–974.
   PubMed Web of Science ®Google Scholar
• Sharma, K. and Kass, D.A., 2014. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circulation research, 115 (1), 79–96.
   PubMed Web of Science ®Google Scholar
• Sokanovic, S.J., et al., 2013. The opposing roles of nitric oxide and cGMP in the age-associated decline in rat testicular steroidogenesis. Endocrinology, 154 (10), 3914–3924.
   PubMed Web of Science ®Google Scholar
• Solomon, S.D., et al., PARAGON-HF Investigators and Committees, 2019. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The New England journal of medicine, 381 (17), 1609–1620.
   PubMed Web of Science ®Google Scholar
• Solomon, S.D., et al., 2012. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The lancet, 380 (9851), 1387–1395.
   PubMed Web of Science ®Google Scholar
• Subramanya, V., et al., 2018. Sex hormone levels and change in left ventricular structure among men and post-menopausal women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas, 108, 37–44.
   PubMed Web of Science ®Google Scholar
• Takimoto, E., et al., 2007. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation, 115 (16), 2159–2169.
   PubMed Web of Science ®Google Scholar
• Takimoto, E., et al., 2005. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature medicine, 11 (2), 214–222.
   PubMed Web of Science ®Google Scholar
• Tsai, E.J. and Kass, D.A., 2009. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacology & therapeutics, 122 (3), 216–238.
   PubMed Web of Science ®Google Scholar
• Udelson, J.E., et al., 2020. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF Randomized Clinical Trial. JAMA, 324 (15), 1522–1531.
   PubMed Web of Science ®Google Scholar
• Ying, W., et al., 2019. Associations between the cyclic guanosine monophosphate pathway and cardiovascular risk factors: MESA. Journal of the American Heart Association, 8, e013149.
   PubMed Web of Science ®Google Scholar
• Ying, W., et al., 2018. Sex hormones and change in N-terminal pro-B-type natriuretic peptide levels: the Multi-Ethnic Study of Atherosclerosis. The journal of clinical endocrinology & metabolism, 103 (11), 4304–4314.
   PubMed Web of Science ®Google Scholar
• Zahabi, A., et al., 2003. Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. Journal of biological chemistry, 278 (48), 47694–47699.
   PubMed Web of Science ®Google Scholar
• Zhang, M., et al., 2010. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. Journal of the American College of Cardiology, 56 (24), 2021–2030.
   PubMed Web of Science ®Google Scholar
• Zhao, D., et al., 2020. Cyclic guanosine monophosphate and risk of incident heart failure and other cardiovascular events: the ARIC Study. Journal of the American Heart Association, 9 (2), e013966.
   PubMed Web of Science ®Google Scholar